Identification

Name
Zonisamide
Accession Number
DB00909  (APRD00004)
Type
Small Molecule
Groups
Approved, Investigational
Description

Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate.

Structure
Thumb
Synonyms
  • 1,2-Benzisoxazole-3-methanesulfonamide
  • 3-(Sulfamoylmethyl)-1,2-benzisoxazole
  • Benzo[d]isoxazol-3-yl-methanesulfonamide
  • Zonisamida
  • Zonisamidum
External IDs
AD-810 / CI-912 / PD-110843
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZonegranCapsule25 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranTablet, orally disintegrating25 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranCapsule50 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranCapsule100 mg/1OralEisai Limited2000-03-27Not applicableUs
ZonegranCapsule100 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranTablet, orally disintegrating100 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranCapsule100 mg/1OralConcordia Pharmaceuticals, Inc2000-03-27Not applicableUs
ZonegranCapsule50 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranTablet, orally disintegrating50 mgOralEisai Limited2005-03-10Not applicableEu
ZonegranCapsule100 mgOralEisai Limited2005-03-10Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ZonisamideCapsule25 mg/1OralMylan Pharmaceuticals2005-12-23Not applicableUs
ZonisamideCapsule50 mg/1OralApotex Corporation2005-12-222018-05-12Us
ZonisamideCapsule25 mg/1OralCadila Pharnmaceuticals2017-11-22Not applicableUs
ZonisamideCapsule50 mg/1OralDirectrx2014-01-01Not applicableUs64679 0946 01 nlmimage10 092004f0
ZonisamideCapsule100 mg/1OralCamber Pharmaceuticals2012-02-21Not applicableUs
ZonisamideCapsule100 mg/1OralNu Care Pharmaceuticals,inc.2006-01-30Not applicableUs
ZonisamideCapsule100 mg/1OralBlue Point Laboratories2014-03-13Not applicableUs
ZonisamideCapsule100 mg/1OralProficient Rx LP2006-03-17Not applicableUs
ZonisamideCapsule100 mg/1OralDirectrx2014-01-012017-11-14Us
ZonisamideCapsule25 mg/1OralWockhardt2006-07-27Not applicableUs
International/Other Brands
Exceglan / Excegram / Excegran
Categories
UNII
459384H98V
CAS number
68291-97-4
Weight
Average: 212.226
Monoisotopic: 212.025562822
Chemical Formula
C8H8N2O3S
InChI Key
UBQNRHZMVUUOMG-UHFFFAOYSA-N
InChI
InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
IUPAC Name
1,2-benzoxazol-3-ylmethanesulfonamide
SMILES
NS(=O)(=O)CC1=NOC2=CC=CC=C12

Pharmacology

Indication

For use as adjunctive treatment of partial seizures in adults with epilepsy.

Associated Conditions
Pharmacodynamics

Zonisamide is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. The precise mechanism by which zonisamide exerts its antiseizure effect is unknown, although it is believed that the drug blocks sodium and calcium channels, which leads to the suppression of neuronal hypersynchronization (i.e. convulsions). Sonisamide has also been found to potentiate dopaminergic and serotonergic neurotransmission but does not appear to potentiate syanptic activity by GABA (gamma amino butyric acid).

Mechanism of action

Zonisamide binds to sodium channels and voltage sensitive calcium channels, which suppresses neuronal depolarization and hypersynchronization. Zonisamide also inhibits carbonic anhydrase to a weaker extent, but such an effect is not thought to contribute substantially to the drug's anticonvulsant activity.

TargetActionsOrganism
ASodium channel protein type 1 subunit alpha
inhibitor
Human
ASodium channel protein type 2 subunit alpha
inhibitor
Human
ASodium channel protein type 3 subunit alpha
inhibitor
Human
ASodium channel protein type 4 subunit alpha
inhibitor
Human
ASodium channel protein type 5 subunit alpha
inhibitor
Human
ASodium channel protein type 9 subunit alpha
inhibitor
Human
ASodium channel protein type 11 subunit alpha
inhibitor
Human
ASodium channel subunit beta-1
inhibitor
Human
ASodium channel subunit beta-2
inhibitor
Human
ASodium channel subunit beta-3
inhibitor
Human
ASodium channel subunit beta-4
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1I
inhibitor
Human
UCarbonic anhydrase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 3
inhibitor
Human
UCarbonic anhydrase 4
inhibitor
Human
UCarbonic anhydrase 5A, mitochondrial
inhibitor
Human
UCarbonic anhydrase 5B, mitochondrial
inhibitor
Human
UCarbonic anhydrase 6
inhibitor
Human
UCarbonic anhydrase 7
inhibitor
Human
UCarbonic anhydrase-related protein
inhibitor
Human
UCarbonic anhydrase 9
inhibitor
Human
UCarbonic anhydrase-related protein 10
inhibitor
Human
UCarbonic anhydrase-related protein 11
inhibitor
Human
UCarbonic anhydrase 12
inhibitor
Human
UCarbonic anhydrase 13
inhibitor
Human
UCarbonic anhydrase 14
inhibitor
Human
UAmine oxidase [flavin-containing] B
inhibitor
Human
UAmine oxidase [flavin-containing] A
inhibitor
Human
Absorption

Variable, yet relatively rapid rate of absorption with a time to peak concentration of 2.8-3.9 hours. Food has no effect on the bioavailability of zonisamide.

Volume of distribution
  • 1.45 L/kg
Protein binding

40% (at concentrations of 1.0-7.0 µg/mL)

Metabolism

Primarily hepatic through cytochrome P450 isoenzyme 3A4 (CYP3A4). Undergoes acetylation and reduction, forming N-acetyl zonisamide, and the open-ring metabolite 2–sulfamoylacetyl phenol, respectively.

Route of elimination

Zonisamide is excreted primarily in urine as parent drug and as the glucuronide of a metabolite.

Half life

63 hours

Clearance
  • 0.30 - 0.35 mL/min/kg [patients not receiving enzyme-inducing antiepilepsy drugs (AEDs)]
  • 0.35 - 0.5 mL/min/kg [Concomitant administration of phenytoin and carbamazepine]
Toxicity

Symptoms of overdose include diminished breathing, loss of consciousness, low blood pressure, and slow heartbeat.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineZonisamide may increase the excretion rate of 3-isobutyl-1-methyl-7H-xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
6-O-benzylguanineZonisamide may increase the excretion rate of 6-O-benzylguanine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
7-DeazaguanineZonisamide may increase the excretion rate of 7-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Zonisamide is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Zonisamide is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
7,9-DimethylguanineZonisamide may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-azaguanineZonisamide may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
8-chlorotheophyllineZonisamide may increase the excretion rate of 8-chlorotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
9-DeazaguanineZonisamide may increase the excretion rate of 9-Deazaguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
9-MethylguanineZonisamide may increase the excretion rate of 9-Methylguanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Zonisamide.Investigational
AcefyllineZonisamide may increase the excretion rate of Acefylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Zonisamide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Acetylglycinamide chloral hydrate.Experimental
AcyclovirZonisamide may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
AdinazolamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Zonisamide is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alaproclate.Experimental
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Zonisamide.Investigational
AlcuroniumZonisamide may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Zonisamide.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Zonisamide.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Zonisamide.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe metabolism of Zonisamide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Zonisamide.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe metabolism of Zonisamide can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Zonisamide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Amphetamine.Approved, Illicit, Investigational
Amphotericin BZonisamide may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Zonisamide can be decreased when combined with Amprenavir.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Aniracetam.Experimental
ApalutamideThe serum concentration of Zonisamide can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Zonisamide is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Zonisamide can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Zonisamide is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Zonisamide.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Zonisamide.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Zonisamide.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Zonisamide.Approved
AtazanavirThe metabolism of Zonisamide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Atomoxetine.Approved
AtracuriumZonisamide may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateZonisamide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Azaperone.Investigational, Vet Approved
AzathioprineZonisamide may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.Approved
AZD-3043The risk or severity of adverse effects can be increased when Zonisamide is combined with AZD-3043.Investigational
AzelastineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Zonisamide.Approved
BamifyllineZonisamide may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BarbexacloneThe metabolism of Zonisamide can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Zonisamide can be increased when combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Benperidol.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Zonisamide is combined with Benzyl alcohol.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Zonisamide.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Zonisamide is combined with Bifeprunox.Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Zonisamide.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Zonisamide.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Zonisamide.Approved
BL-1020The risk or severity of adverse effects can be increased when Zonisamide is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Zonisamide can be decreased when combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Zonisamide can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Zonisamide is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Zonisamide is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Zonisamide.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Zonisamide.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Zonisamide.Approved, Investigational
BromotheophyllineZonisamide may increase the excretion rate of Bromotheophylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
BromperidolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Zonisamide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Zonisamide.Investigational
BufotenineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Bufotenine.Experimental, Illicit
BufyllineZonisamide may increase the excretion rate of Bufylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Zonisamide.Investigational
BuprenorphineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Zonisamide is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Zonisamide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Zonisamide.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Zonisamide.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Zonisamide.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zonisamide.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Butriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cabergoline.Approved
CafedrineZonisamide may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.Investigational
CaffeineZonisamide may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.Approved
Calcium AcetateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium Phosphate.Approved
CamazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Camazepam.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Zonisamide is combined with Captodiame.Approved, Investigational
CarbamazepineThe serum concentration of Zonisamide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Zonisamide.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Zonisamide.Approved, Investigational
CarbromalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Zonisamide is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Zonisamide.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Caroxazone.Withdrawn
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Zonisamide.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Zonisamide.Approved, Investigational, Nutraceutical, Vet Approved
CathinoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cathinone.Illicit
CeritinibThe serum concentration of Zonisamide can be increased when it is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Zonisamide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Zonisamide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Zonisamide.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zonisamide.Approved
CilansetronThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cilansetron.Investigational
CimetidineThe serum concentration of Zonisamide can be increased when it is combined with Cimetidine.Approved, Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumZonisamide may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Zonisamide is combined with Citalopram.Approved
ClarithromycinThe metabolism of Zonisamide can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Zonisamide.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Zonisamide.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Zonisamide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Zonisamide is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Zonisamide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Zonisamide.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Zonisamide.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Zonisamide can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Zonisamide.Approved
CobicistatThe metabolism of Zonisamide can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Zonisamide.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Zonisamide.Approved, Investigational
CrizotinibThe metabolism of Zonisamide can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Zonisamide can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zonisamide.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Zonisamide.Approved
DabrafenibThe serum concentration of Zonisamide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Zonisamide can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Zonisamide.Approved, Investigational, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Zonisamide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Zonisamide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Zonisamide can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Zonisamide is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Zonisamide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Zonisamide can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Zonisamide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Zonisamide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Zonisamide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dextofisopam.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Zonisamide.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Zonisamide is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Zonisamide.Approved, Illicit
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Zonisamide.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Zonisamide can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Zonisamide.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Zonisamide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dixyrazine.Experimental
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Zonisamide.Approved
DolasetronThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Zonisamide is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Zonisamide is combined with Donepezil.Approved
DopamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dotarizine.Investigational
DoxacuriumZonisamide may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Zonisamide.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Zonisamide.Approved, Investigational
DoxofyllineZonisamide may increase the excretion rate of Doxofylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
DoxycyclineThe metabolism of Zonisamide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Zonisamide is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Illicit
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Zonisamide.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dyclonine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Zonisamide.Approved
EcopipamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Edivoxetine.Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Zonisamide.Approved
EletriptanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Zonisamide is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Zonisamide.Approved, Investigational
EntecavirZonisamide may increase the excretion rate of Entecavir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
EnzalutamideThe serum concentration of Zonisamide can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ergonovine.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Zonisamide.Approved
ErythromycinThe metabolism of Zonisamide can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Zonisamide is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Zonisamide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Zonisamide.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etacrynic acid.Approved, Investigational
EtamiphyllineZonisamide may increase the excretion rate of Etamiphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
EthadioneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ethadione.Experimental
EthanolZonisamide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Zonisamide can be decreased when it is combined with Ethinyl Estradiol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Zonisamide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Zonisamide.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Zonisamide can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenethyllineZonisamide may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
FenfluramineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Zonisamide.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Zonisamide.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Zonisamide can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Zonisamide.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zonisamide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Zonisamide.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Zonisamide.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Zonisamide.Experimental
FluvoxamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Zonisamide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Zonisamide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Zonisamide can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Frovatriptan.Approved, Investigational
FurafyllineZonisamide may increase the excretion rate of Furafylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Zonisamide can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Zonisamide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Zonisamide is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Gaboxadol.Investigational
GallamineZonisamide may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideZonisamide may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Zonisamide.Approved, Illicit, Investigational
GanciclovirZonisamide may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Zonisamide is combined with Gedocarnil.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Zonisamide is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Zonisamide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Glutethimide.Approved, Illicit
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Zonisamide.Approved, Investigational
GranisetronThe risk or severity of adverse effects can be increased when Zonisamide is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Guanfacine.Approved, Investigational
GuanineZonisamide may increase the excretion rate of Guanine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zonisamide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Zonisamide is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Zonisamide is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Hexapropymate.Experimental
HexobarbitalThe metabolism of Zonisamide can be increased when combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Hydracarbazine.Experimental
HydrocodoneZonisamide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Zonisamide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Zonisamide is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Hypericin.Investigational
HypoxanthineZonisamide may increase the excretion rate of Hypoxanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
IdalopirdineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Zonisamide can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Zonisamide.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Imagabalin.Investigational
ImatinibThe metabolism of Zonisamide can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Zonisamide.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Zonisamide can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Zonisamide is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Zonisamide.Withdrawn
IprazochromeThe risk or severity of adverse effects can be increased when Zonisamide is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Zonisamide is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Zonisamide is combined with Iproniazid.Withdrawn
IsavuconazoleThe serum concentration of Zonisamide can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Zonisamide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Zonisamide is combined with Isocarboxazid.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Zonisamide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Zonisamide.Approved, Vet Approved
IsoniazidThe metabolism of Zonisamide can be decreased when combined with Isoniazid.Approved, Investigational
ItraconazoleThe metabolism of Zonisamide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Zonisamide can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zonisamide.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Zonisamide can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when Zonisamide is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Zonisamide.Approved
LacosamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Zonisamide.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Zonisamide.Approved
LamotrigineThe serum concentration of Zonisamide can be decreased when it is combined with Lamotrigine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levetiracetam.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Zonisamide is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Zonisamide.Approved
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Zonisamide.Approved
LincomycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Zonisamide is combined with Linezolid.Approved, Investigational
LisofyllineZonisamide may increase the excretion rate of Lisofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LisurideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lithium cation.Experimental
LobucavirZonisamide may increase the excretion rate of Lobucavir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Zonisamide can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Zonisamide can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Zonisamide.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Zonisamide.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Zonisamide can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lortalamine.Experimental
LovastatinThe metabolism of Zonisamide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zonisamide.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Zonisamide.Approved, Investigational
LuliconazoleThe serum concentration of Zonisamide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Zonisamide can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Zonisamide.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Zonisamide is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Zonisamide is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Zonisamide.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium phosphate.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Zonisamide is combined with Magnesium salicylate.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Zonisamide can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Magnesium Trisilicate.Approved
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Zonisamide.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Maprotiline.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Zonisamide.Approved
MedazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Medifoxamine.Experimental
MefloquineThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Zonisamide is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Zonisamide is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Melperone.Approved, Investigational
MephenesinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mephenoxalone.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mephenytoin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zonisamide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zonisamide.Approved
MetergolineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Zonisamide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zonisamide.Approved, Vet Approved
MethohexitalThe metabolism of Zonisamide can be increased when combined with Methohexital.Approved
MethotrimeprazineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methsuximide.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Zonisamide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe metabolism of Zonisamide can be increased when combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methysergide.Approved
MetocurineZonisamide may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideZonisamide may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetyrosineZonisamide may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Mianserin.Approved, Investigational
MibefradilThe metabolism of Zonisamide can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Zonisamide can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Zonisamide.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Midomafetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Zonisamide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Zonisamide is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Minaprine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Zonisamide.Approved, Vet Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
MirtazapineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Zonisamide can be decreased when it is combined with Mitotane.Approved
MivacuriumZonisamide may increase the neuromuscular blocking activities of Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Zonisamide is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Zonisamide is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Zonisamide can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Zonisamide.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Zonisamide is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
NafcillinThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Zonisamide is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Zonisamide.Approved
NaloxoneThe metabolism of Zonisamide can be decreased when combined with Naloxone.Approved, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Nefiracetam.Investigational
NelfinavirThe serum concentration of Zonisamide can be decreased when it is combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Zonisamide is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Zonisamide can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Zonisamide can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Niaprazine.Experimental
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Zonisamide.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Zonisamide.Approved, Investigational
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Zonisamide.Experimental
NilotinibThe metabolism of Zonisamide can be decreased when combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Zonisamide.Approved
NitroprussideZonisamide may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Zonisamide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Nordazepam.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Zonisamide.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Zonisamide.Approved, Investigational
OlaparibThe metabolism of Zonisamide can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zonisamide.Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Zonisamide.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Zonisamide is combined with Opium.Approved, Illicit
OrlistatOrlistat can cause a decrease in the absorption of Zonisamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineZonisamide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Zonisamide is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Zonisamide is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Zonisamide can be increased when it is combined with Osimertinib.Approved
OxaflozaneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zonisamide.Approved
OxcarbazepineThe serum concentration of Zonisamide can be decreased when it is combined with Oxcarbazepine.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Zonisamide.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Zonisamide is combined with Oxprenolol.Approved
OxtriphyllineZonisamide may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Zonisamide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Zonisamide.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Oxypertine.Experimental
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Zonisamide.Investigational, Withdrawn
OxytetracyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Zonisamide can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Zonisamide.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Zonisamide is combined with Palonosetron.Approved, Investigational
PancuroniumZonisamide may increase the neuromuscular blocking activities of Pancuronium.Approved
ParaldehydeZonisamide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.Approved, Investigational
PeldesineZonisamide may increase the excretion rate of Peldesine which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
PemetrexedZonisamide may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Zonisamide is combined with Penbutolol.Approved, Investigational
PenciclovirZonisamide may increase the excretion rate of Penciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Penimepicycline.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Zonisamide.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Zonisamide.Approved, Vet Approved
PentifyllineZonisamide may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PentobarbitalThe metabolism of Zonisamide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoxifyllineZonisamide may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
PerazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Zonisamide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Zonisamide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Zonisamide.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pheniprazine.Withdrawn
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Zonisamide.Approved, Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Zonisamide.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Phentermine.Approved, Illicit
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Zonisamide.Approved
PhenytoinPhenytoin may increase the excretion rate of Zonisamide which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Zonisamide.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Zonisamide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pipamperone.Approved, Investigational
PipecuroniumZonisamide may increase the neuromuscular blocking activities of Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pirlindole.Approved
PitolisantThe serum concentration of Zonisamide can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Zonisamide.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Zonisamide.Approved, Investigational
PlazomicinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Plazomicin.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Zonisamide.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Zonisamide.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Zonisamide.Approved, Vet Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Zonisamide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Zonisamide.Approved, Investigational
PramipexoleZonisamide may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Zonisamide.Approved
PregabalinThe therapeutic efficacy of Zonisamide can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pridinol.Experimental
PrimidoneThe serum concentration of Zonisamide can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zonisamide.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Zonisamide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Zonisamide is combined with Propanidid.Experimental
PropentofyllineZonisamide may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Zonisamide.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Zonisamide.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Propiopromazine.Vet Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Zonisamide.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Zonisamide.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when Zonisamide is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zonisamide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Proxibarbal.Experimental
ProxyphyllineZonisamide may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Zonisamide.Approved
PRX-08066The risk or severity of adverse effects can be increased when Zonisamide is combined with PRX-08066.Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Zonisamide.Approved, Illicit
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Zonisamide.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Zonisamide.Approved, Investigational
QuinineThe metabolism of Zonisamide can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ramosetron.Approved, Investigational
RapacuroniumZonisamide may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Rasagiline.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Zonisamide.Investigational
ReboxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zonisamide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Zonisamide.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ribostamycin.Approved, Investigational
RifampicinThe serum concentration of Zonisamide can be decreased when it is combined with Rifampicin.Approved
RifamycinThe metabolism of Zonisamide can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Zonisamide can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Zonisamide can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Zonisamide is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Zonisamide can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Zonisamide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Zonisamide can be decreased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Rizatriptan.Approved
RocuroniumZonisamide may increase the neuromuscular blocking activities of Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Zonisamide is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Romifidine.Vet Approved
RopiniroleZonisamide may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineZonisamide may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Zonisamide is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Zonisamide.Approved
SafinamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Zonisamide can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Zonisamide is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Zonisamide.Approved, Investigational
SecobarbitalThe metabolism of Zonisamide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Selegiline.Approved, Investigational, Vet Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Zonisamide.Approved
SerotoninThe risk or severity of adverse effects can be increased when Zonisamide is combined with Serotonin.Investigational, Nutraceutical
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Zonisamide.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zonisamide.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Zonisamide.Approved
SiltuximabThe serum concentration of Zonisamide can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Zonisamide can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Zonisamide.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Zonisamide.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Zonisamide.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Zonisamide.Approved
St. John's WortThe serum concentration of Zonisamide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Zonisamide can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zonisamide.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Zonisamide.Approved
SulpirideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sumatriptan.Approved, Investigational
SuvorexantZonisamide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when Zonisamide is combined with Talopram.Experimental
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Zonisamide.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Zonisamide is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Zonisamide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Zonisamide can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Zonisamide.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Zonisamide.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Zonisamide.Approved
Testosterone propionateThe serum concentration of Zonisamide can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
TetracyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tetrodotoxin.Investigational
ThalidomideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineZonisamide may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
TheodrenalineZonisamide may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.Investigational
ThiamylalThe metabolism of Zonisamide can be increased when combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe metabolism of Zonisamide can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Zonisamide.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Zonisamide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Zonisamide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Zonisamide.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tiapride.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Zonisamide.Approved
TipranavirThe serum concentration of Zonisamide can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Zonisamide.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Zonisamide can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tofisopam.Approved
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Zonisamide.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Zonisamide.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tolperisone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Zonisamide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Zonisamide.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Zonisamide.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Zonisamide is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Zonisamide.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Zonisamide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Zonisamide.Experimental
TrimethadioneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Trimethadione.Approved
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Zonisamide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Zonisamide.Approved
TroleandomycinThe metabolism of Zonisamide can be decreased when combined with Troleandomycin.Approved
TropisetronThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tropisetron.Approved, Investigational
TubocurarineZonisamide may increase the neuromuscular blocking activities of Tubocurarine.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Zonisamide.Investigational
Uric AcidZonisamide may increase the excretion rate of Uric Acid which could result in a lower serum level and potentially a reduction in efficacy.Experimental, Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vabicaserin.Investigational
ValaciclovirZonisamide may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValerianThe risk or severity of adverse effects can be increased when Zonisamide is combined with Valerian.Approved, Experimental, Investigational
ValganciclovirZonisamide may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Valnoctamide.Investigational
ValomaciclovirZonisamide may increase the excretion rate of Valomaciclovir which could result in a lower serum level and potentially a reduction in efficacy.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Zonisamide is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vancomycin.Approved
VecuroniumZonisamide may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Zonisamide.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Veralipride.Experimental
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Zonisamide.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vinylbital.Experimental
VoriconazoleThe metabolism of Zonisamide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vortioxetine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Zonisamide is combined with Wortmannin.Experimental
XanthineZonisamide may increase the excretion rate of Xanthine which could result in a lower serum level and potentially a reduction in efficacy.Experimental
XP19986The risk or severity of adverse effects can be increased when Zonisamide is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Zonisamide is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Zonisamide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zonisamide can be decreased when it is combined with Zidovudine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Zonisamide.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zonisamide is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zonisamide is combined with Zolmitriptan.Approved, Investigational
ZolpidemZonisamide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Zonisamide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zonisamide is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Zonisamide.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Tamar Nidam, "Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms." U.S. Patent US20030114682, issued June 19, 2003.

US20030114682
General References
  1. Murata M, Horiuchi E, Kanazawa I: Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res. 2001 Dec;41(4):397-9. [PubMed:11755227]
  2. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003 Apr 9;289(14):1820-5. [PubMed:12684361]
  3. Hasegawa H: Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr Med Res Opin. 2004 May;20(5):577-80. [PubMed:15140322]
  4. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  5. Ueda Y, Doi T, Tokumaru J, Willmore LJ: Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):1-6. [PubMed:12941455]
  6. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  7. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  8. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  9. Peters DH, Sorkin EM: Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 1993 May;45(5):760-87. [PubMed:7686468]
  10. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
External Links
Human Metabolome Database
HMDB0015045
KEGG Drug
D00538
KEGG Compound
C07504
PubChem Compound
5734
PubChem Substance
46505278
ChemSpider
5532
BindingDB
10888
ChEBI
10127
ChEMBL
CHEMBL750
Therapeutic Targets Database
DAP000500
PharmGKB
PA451978
HET
ZON
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Zonisamide
ATC Codes
N03AX15 — Zonisamide
PDB Entries
3po7
FDA label
Download (124 KB)
MSDS
Download (58.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers2
1RecruitingTreatmentAlcohol Use Disorder (AUD)1
1, 2CompletedNot AvailableDependence, Cocaine1
1, 2CompletedTreatmentNicotine Dependence1
1, 2WithdrawnPreventionNoise Induced Hearing Loss1
2CompletedPreventionMigrainous Headache1
2CompletedTreatmentAlcoholism1
2CompletedTreatmentBMI >30 kg/m2 / Obstructive Sleep Apnea (OSA) / Sleep Apnea Syndrome1
2CompletedTreatmentTremor, Essential1
2Not Yet RecruitingTreatmentAlcohol Use Disorder (AUD) / Post Traumatic Stress Disorder (PTSD)1
2RecruitingTreatmentAlcohol Dependence / Post-Traumatic Stress Disorder (PTSD)1
2TerminatedTreatmentAlcohol Abuse / Alcohol Dependence / Alcoholism1
2TerminatedTreatmentAlcohol Use Disorders (AUD) / Bipolar Disorder (BD)1
2, 3Unknown StatusTreatmentParkinson's Disease (PD)1
3CompletedPreventionSchizoaffective Disorders / Schizophrenic Disorders1
3CompletedPreventionWeight gain therapy1
3CompletedTreatmentBinge Eating Disorder Associated With Obesity1
3CompletedTreatmentEpilepsies3
3CompletedTreatmentEpilepsy, Complex Partial1
3CompletedTreatmentEpilepsy; Paediatric Partial Onset Seizures1
3CompletedTreatmentMyoclonus Dystonia1
3CompletedTreatmentPartial onset seizure Epilepsy2
3RecruitingTreatmentAlcohol Dependence1
3RecruitingTreatmentAlcohol Use Disorder (AUD)1
3TerminatedTreatmentEpilepsies2
4Active Not RecruitingTreatmentEpilepsies1
4CompletedNot AvailablePartial, Generalized and Combined Seizures1
4CompletedTreatmentAlcohol Abuse / Alcohol Dependence / Alcoholism1
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentEpilepsies6
4CompletedTreatmentEpilepsy, Localization Related1
4RecruitingTreatmentDyskinesias / Parkinson's Disease (PD) / Parkinsonism1
4RecruitingTreatmentEpilepsies1
4TerminatedTreatmentBipolar Disorder (BD)1
4TerminatedTreatmentEpilepsies1
4WithdrawnTreatmentFibromyalgia / Migraines1
Not AvailableCompletedNot AvailableAlcoholism1
Not AvailableCompletedNot AvailableEpilepsies1
Not AvailableCompletedNot AvailablePartial onset seizure Epilepsy1
Not AvailableCompletedTreatmentBMI >30 kg/m21
Not AvailableTerminatedTreatmentTremor, Essential1
Not AvailableUnknown StatusHealth Services ResearchMigraines1

Pharmacoeconomics

Manufacturers
  • Eisai inc
  • Alphapharm party ltd
  • Apotex inc etobicoke site
  • Banner pharmacaps inc
  • Barr laboratories inc
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Glenmark generics inc usa
  • Invagen pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Wockhardt ltd
  • Zydus pharmaceuticals usa inc
Packagers
  • Alphapharm Party Ltd.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Barr Pharmaceuticals
  • Bryant Ranch Prepack
  • Corepharma LLC
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Eisai Inc.
  • Elan Pharmaceuticals Inc.
  • Eon Labs
  • Genpharm LP
  • Glenmark Generics Ltd.
  • Heartland Repack Services LLC
  • InvaGen Pharmaceuticals Inc.
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Resource Optimization and Innovation LLC
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
Tablet, orally disintegratingOral100 mg
Tablet, orally disintegratingOral25 mg
Tablet, orally disintegratingOral300 mg
Tablet, orally disintegratingOral50 mg
CapsuleOral100 mg/1
CapsuleOral25 mg/1
CapsuleOral50 mg/1
CapsuleOral100 mg
CapsuleOral25 mg
CapsuleOral50 mg
Prices
Unit descriptionCostUnit
Zonegran 100 mg capsule3.33USD capsule
Zonisamide 100 mg capsule2.24USD capsule
Zonegran 50 mg capsule1.22USD capsule
Zonisamide 50 mg capsule1.12USD capsule
Zonegran 25 mg capsule0.94USD capsule
Zonisamide 25 mg capsule0.56USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)161-163 °CNot Available
water solubility0.8 mg/mLNot Available
logP0.5Not Available
pKa10.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.09 mg/mLALOGPS
logP0.67ALOGPS
logP0.11ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)9.84ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.19 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity50.3 m3·mol-1ChemAxon
Polarizability19.48 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9755
Caco-2 permeable-0.6385
P-glycoprotein substrateNon-substrate0.8681
P-glycoprotein inhibitor INon-inhibitor0.9258
P-glycoprotein inhibitor IINon-inhibitor0.9513
Renal organic cation transporterNon-inhibitor0.8463
CYP450 2C9 substrateNon-substrate0.8828
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5419
CYP450 1A2 substrateNon-inhibitor0.5762
CYP450 2C9 inhibitorNon-inhibitor0.697
CYP450 2D6 inhibitorNon-inhibitor0.8081
CYP450 2C19 inhibitorNon-inhibitor0.6007
CYP450 3A4 inhibitorNon-inhibitor0.8141
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7315
Ames testNon AMES toxic0.6276
CarcinogenicityNon-carcinogens0.7572
BiodegradationNot ready biodegradable0.9708
Rat acute toxicity2.0592 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8549
hERG inhibition (predictor II)Non-inhibitor0.8937
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0900000000-c05ae650c884adcaba5a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0900000000-477908537d156d43e3a9
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0900000000-f537644668fbc9b2e02b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-1900000000-6359b9c8e68ec5477b26
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-3900000000-db3cf8881465259c48ca
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-6900000000-cd4c8b86f36ce38b3a49
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0930000000-a0dd3941aea211aeb201
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0900000000-88938a9c69a2d4daf36a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-2900000000-3440f1648bff05d21a31
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-5900000000-a727755cf1e18764e9d0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udj-9600000000-aa8a18a9ab17508f689d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udj-9200000000-41d7e769a93444ba3751
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0gx0-0940000000-22533c93dd06de52f6a8

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzisoxazoles. These are aromatic compounds containing a benzene ring fused to an isoxazole ring. Isoxazole is five-membered ring with three carbon atoms, and an oxygen atom next to a nitrogen atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzisoxazoles
Sub Class
Not Available
Direct Parent
Benzisoxazoles
Alternative Parents
Organosulfonamides / Organic sulfonamides / Benzenoids / Isoxazoles / Heteroaromatic compounds / Aminosulfonyl compounds / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Benzisoxazole / Organic sulfonic acid amide / Organosulfonic acid amide / Benzenoid / Azole / Isoxazole / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl / Aminosulfonyl compound
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfonamide, 1,2-benzoxazoles (CHEBI:10127)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN1A
Uniprot ID
P35498
Uniprot Name
Sodium channel protein type 1 subunit alpha
Molecular Weight
228969.49 Da
References
  1. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  2. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  3. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  4. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN2A
Uniprot ID
Q99250
Uniprot Name
Sodium channel protein type 2 subunit alpha
Molecular Weight
227972.64 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN3A
Uniprot ID
Q9NY46
Uniprot Name
Sodium channel protein type 3 subunit alpha
Molecular Weight
226291.905 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN4A
Uniprot ID
P35499
Uniprot Name
Sodium channel protein type 4 subunit alpha
Molecular Weight
208059.175 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
Gene Name
SCN9A
Uniprot ID
Q15858
Uniprot Name
Sodium channel protein type 9 subunit alpha
Molecular Weight
226370.175 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN11A
Uniprot ID
Q9UI33
Uniprot Name
Sodium channel protein type 11 subunit alpha
Molecular Weight
204919.66 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in purkinje myocyte action potential
Specific Function
Crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the sodium channel. The subunit beta-1 can modulate multiple alpha subunit isoforms from brain, skele...
Gene Name
SCN1B
Uniprot ID
Q07699
Uniprot Name
Sodium channel subunit beta-1
Molecular Weight
24706.955 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in cardiac muscle cell action potential
Specific Function
Crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the sodium channel. The subunit beta-2 causes an increase in the plasma membrane surface area and in ...
Gene Name
SCN2B
Uniprot ID
O60939
Uniprot Name
Sodium channel subunit beta-2
Molecular Weight
24325.69 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in cardiac muscle cell action potential
Specific Function
Modulates channel gating kinetics. Causes unique persistent sodium currents. Inactivates the sodium channel opening more slowly than the subunit beta-1. Its association with neurofascin may target ...
Gene Name
SCN3B
Uniprot ID
Q9NY72
Uniprot Name
Sodium channel subunit beta-3
Molecular Weight
24702.08 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in cardiac muscle cell action potential
Specific Function
Modulates channel gating kinetics. Causes negative shifts in the voltage dependence of activation of certain alpha sodium channels, but does not affect the voltage dependence of inactivation. Modul...
Gene Name
SCN4B
Uniprot ID
Q8IWT1
Uniprot Name
Sodium channel subunit beta-4
Molecular Weight
24968.755 Da
References
  1. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  4. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  4. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  5. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  6. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  7. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  8. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  9. Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. [PubMed:14965331]
  10. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]
  11. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  12. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  4. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. [PubMed:14965331]
  8. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]
  9. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  10. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1I
Uniprot ID
Q9P0X4
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1I
Molecular Weight
245100.8 Da
References
  1. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  2. Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. doi: 10.1517/17425255.4.4.493 . [PubMed:18433351]
  3. Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. [PubMed:14704463]
  4. Janszky J: [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. Ideggyogy Sz. 2009 Nov 30;62(11-12):383-9. [PubMed:20025128]
  5. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  6. Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. [PubMed:15511691]
  7. Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. [PubMed:14965331]
  8. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]
  9. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  10. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
Details
15. Carbonic anhydrase 1
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name
CA1
Uniprot ID
P00915
Uniprot Name
Carbonic anhydrase 1
Molecular Weight
28870.0 Da
References
  1. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [PubMed:15837316]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Shank RP, Smith-Swintosky VL, Maryanoff BE: Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem. 2008 Apr;23(2):271-6. doi: 10.1080/14756360701507001 . [PubMed:18343915]
  4. Masuda Y, Karasawa T: Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung. 1993 Apr;43(4):416-8. [PubMed:8494570]
  5. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  6. Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15. [PubMed:18162396]
  7. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  8. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
16. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Shank RP, Smith-Swintosky VL, Maryanoff BE: Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem. 2008 Apr;23(2):271-6. doi: 10.1080/14756360701507001 . [PubMed:18343915]
  4. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [PubMed:15837316]
  5. Masuda Y, Karasawa T: Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung. 1993 Apr;43(4):416-8. [PubMed:8494570]
  6. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  7. Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15. [PubMed:18162396]
  8. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  9. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
17. Carbonic anhydrase 3
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA3
Uniprot ID
P07451
Uniprot Name
Carbonic anhydrase 3
Molecular Weight
29557.215 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15. [PubMed:18162396]
  5. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  6. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
18. Carbonic anhydrase 4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina an...
Gene Name
CA4
Uniprot ID
P22748
Uniprot Name
Carbonic anhydrase 4
Molecular Weight
35032.075 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Low activity.
Gene Name
CA5A
Uniprot ID
P35218
Uniprot Name
Carbonic anhydrase 5A, mitochondrial
Molecular Weight
34750.21 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [PubMed:15837316]
  4. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  5. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  6. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA5B
Uniprot ID
Q9Y2D0
Uniprot Name
Carbonic anhydrase 5B, mitochondrial
Molecular Weight
36433.43 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20. [PubMed:15837316]
  4. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  5. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  6. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
21. Carbonic anhydrase 6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Its role in saliva is unknown.
Gene Name
CA6
Uniprot ID
P23280
Uniprot Name
Carbonic anhydrase 6
Molecular Weight
35366.615 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
22. Carbonic anhydrase 7
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA7
Uniprot ID
P43166
Uniprot Name
Carbonic anhydrase 7
Molecular Weight
29658.235 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Does not have a carbonic anhydrase catalytic activity.
Gene Name
CA8
Uniprot ID
P35219
Uniprot Name
Carbonic anhydrase-related protein
Molecular Weight
32972.915 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
24. Carbonic anhydrase 9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervic...
Gene Name
CA9
Uniprot ID
Q16790
Uniprot Name
Carbonic anhydrase 9
Molecular Weight
49697.36 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Not Available
Specific Function
Does not have a catalytic activity.
Gene Name
CA10
Uniprot ID
Q9NS85
Uniprot Name
Carbonic anhydrase-related protein 10
Molecular Weight
37562.655 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Not Available
Specific Function
Does not have a catalytic activity.
Gene Name
CA11
Uniprot ID
O75493
Uniprot Name
Carbonic anhydrase-related protein 11
Molecular Weight
36237.885 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
27. Carbonic anhydrase 12
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA12
Uniprot ID
O43570
Uniprot Name
Carbonic anhydrase 12
Molecular Weight
39450.615 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
28. Carbonic anhydrase 13
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA13
Uniprot ID
Q8N1Q1
Uniprot Name
Carbonic anhydrase 13
Molecular Weight
29442.895 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Details
29. Carbonic anhydrase 14
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA14
Uniprot ID
Q9ULX7
Uniprot Name
Carbonic anhydrase 14
Molecular Weight
37667.37 Da
References
  1. De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21. doi: 10.1111/j.1747-0285.2009.00857.x. [PubMed:19703035]
  2. Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92. doi: 10.1517/14728214.13.2.383 . [PubMed:18537527]
  3. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
  4. Biton V: Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40. [PubMed:17762320]
  5. Authors unspecified: Zonisamide: new drug. No advantage in refractory partial epilepsy. Prescrire Int. 2007 Jun;16(89):95-7. [PubMed:17582922]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Sonsalla PK, Wong LY, Winnik B, Buckley B: The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp Neurol. 2010 Feb;221(2):329-34. doi: 10.1016/j.expneurol.2009.11.018. Epub 2009 Dec 4. [PubMed:19948168]
  2. Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004;10(6):687-93. [PubMed:14965331]
  3. Murata M, Horiuchi E, Kanazawa I: Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res. 2001 Dec;41(4):397-9. [PubMed:11755227]
  4. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995 Nov;22(3):193-205. [PubMed:8991786]
  5. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]
  6. Okada M: [Effects of carbamazepine and zonisamide on dopaminergic system in rat striatum and hippocampus]. Nihon Shinkei Seishin Yakurigaku Zasshi. 1994 Oct;14(5):337-54. [PubMed:7856330]
  7. Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. [PubMed:18782051]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y: Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995 Nov;22(3):193-205. [PubMed:8991786]
  2. Murata M: Zonisamide: a new drug for Parkinson's disease. Drugs Today (Barc). 2010 Apr;46(4):251-8. doi: 10.1358/dot.2010.46.4.1490077. [PubMed:20502722]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M: Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol. 1993 Jul;44(1):216-21. [PubMed:8341274]
  2. Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. doi: 10.1517/14656560903468728. [PubMed:20001433]
  3. Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20. [PubMed:19557119]
  4. Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M: Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83. [PubMed:9626925]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xanthine dehydrogenase activity
Specific Function
Oxidase with broad substrate specificity, oxidizing aromatic azaheterocycles, such as N1-methylnicotinamide and N-methylphthalazinium, as well as aldehydes, such as benzaldehyde, retinal, pyridoxal...
Gene Name
AOX1
Uniprot ID
Q06278
Uniprot Name
Aldehyde oxidase
Molecular Weight
147916.735 Da
References
  1. Sugihara K, Kitamura S, Tatsumi K: Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Dispos. 1996 Feb;24(2):199-202. [PubMed:8742231]
  2. Kitamura S, Ohashi KNK, Sugihara K, Hosokawa R, Akagawa Y, Ohta S: Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver. Biol Pharm Bull. 2001 Jul;24(7):856-9. [PubMed:11456132]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Interactions [Link]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:29